UA65522C2 - Inner cellular isoform of interleukin-1 receptor antagonist - Google Patents

Inner cellular isoform of interleukin-1 receptor antagonist Download PDF

Info

Publication number: UA65522C2
Authority: UA; Ukraine
Prior art keywords: sequence; polypeptide; isi; cells; antagonist
Prior art date: 1994-10-13

Application number

UA97052129A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-13

Filing date

1995-12-10

Publication date

2004-04-15

1995-12-10 Application filed by Applied Research Systems filed Critical Applied Research Systems

2004-04-15 Publication of UA65522C2 publication Critical patent/UA65522C2/uk

Links

239000003407 interleukin 1 receptor blocking agent Substances 0.000 title abstract 2
230000001413 cellular effect Effects 0.000 title description 2
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 title 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 title 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 title 1
102000001708 Protein Isoforms Human genes 0.000 title 1
108010029485 Protein Isoforms Proteins 0.000 title 1
238000000034 method Methods 0.000 claims abstract description 18
230000007170 pathology Effects 0.000 claims abstract description 13
108020004511 Recombinant DNA Proteins 0.000 claims abstract 2
230000000694 effects Effects 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
229920001184 polypeptide Polymers 0.000 claims description 10
102000004196 processed proteins & peptides Human genes 0.000 claims description 9
208000030507 AIDS Diseases 0.000 claims description 7
230000003834 intracellular effect Effects 0.000 claims description 7
230000005764 inhibitory process Effects 0.000 claims description 6
206010040070 Septic Shock Diseases 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
229940044551 receptor antagonist Drugs 0.000 claims description 3
239000002464 receptor antagonist Substances 0.000 claims description 3
230000001363 autoimmune Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
108020004414 DNA Proteins 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
101100042944 Arabidopsis thaliana SOB5 gene Proteins 0.000 claims 1
229940118432 Interleukin receptor antagonist Drugs 0.000 claims 1
206010052779 Transplant rejections Diseases 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000008105 immune reaction Effects 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
239000005557 antagonist Substances 0.000 abstract description 18
102000000589 Interleukin-1 Human genes 0.000 abstract description 5
108010002352 Interleukin-1 Proteins 0.000 abstract description 5
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 2
230000000069 prophylactic effect Effects 0.000 abstract description 2
230000001225 therapeutic effect Effects 0.000 abstract description 2
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 abstract 1
229940124084 Interleukin 1 antagonist Drugs 0.000 abstract 1
102100039065 Interleukin-1 beta Human genes 0.000 abstract 1
230000018276 interleukin-1 production Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 29
150000001413 amino acids Chemical class 0.000 description 25
108090000623 proteins and genes Proteins 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 21
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108091034117 Oligonucleotide Proteins 0.000 description 13
239000000047 product Substances 0.000 description 11
210000001616 monocyte Anatomy 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
230000003321 amplification Effects 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
108010024212 E-Selectin Proteins 0.000 description 8
102100023471 E-selectin Human genes 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000006166 lysate Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000001262 western blot Methods 0.000 description 4
108020004705 Codon Proteins 0.000 description 3
241000023813 Isia Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000005056 cell body Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
241000283707 Capra Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000764773 Inna Species 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003622 mature neutrocyte Anatomy 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000004983 pleiotropic effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
241000786798 Atya Species 0.000 description 1
241000283725 Bos Species 0.000 description 1
101100116570 Caenorhabditis elegans cup-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
101100116572 Drosophila melanogaster Der-1 gene Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108700005087 Homeobox Genes Proteins 0.000 description 1
101001134172 Homo sapiens Otoancorin Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000283162 Inia geoffrensis Species 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
101100296015 Mus musculus Ovos gene Proteins 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
241000468053 Obodhiang virus Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
102100034199 Otoancorin Human genes 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
244000117054 Rungia klossii Species 0.000 description 1
235000002492 Rungia klossii Nutrition 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
241000219995 Wisteria Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000000720 eyelash Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
235000019988 mead Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Oncology (AREA)
Hematology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)

UA97052129A 1994-10-13 1995-12-10 Inner cellular isoform of interleukin-1 receptor antagonist UA65522C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI942097A IT1270662B (it)	1994-10-13	1994-10-13	Antagonista della interleuchina-1
PCT/EP1995/004023 WO1996012022A1 (en)	1994-10-13	1995-10-12	Intracellular isoform of the interleukin-1 receptor antagonist

Publications (1)

Publication Number	Publication Date
UA65522C2 true UA65522C2 (en)	2004-04-15

Family

ID=11369705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97052129A UA65522C2 (en)	1994-10-13	1995-12-10	Inner cellular isoform of interleukin-1 receptor antagonist

Country Status (18)

Country	Link
US (1)	US5739282A (de)
EP (1)	EP0786002B1 (de)
JP (1)	JPH10509306A (de)
KR (1)	KR100237936B1 (de)
CN (2)	CN100363053C (de)
AT (1)	ATE303439T1 (de)
BR (1)	BR9509317A (de)
CA (1)	CA2202470C (de)
DE (1)	DE69534419T2 (de)
EE (1)	EE03697B1 (de)
ES (1)	ES2243942T3 (de)
IT (1)	IT1270662B (de)
MX (1)	MX9702616A (de)
NO (1)	NO320494B1 (de)
PT (1)	PT786002E (de)
RU (1)	RU2193064C2 (de)
UA (1)	UA65522C2 (de)
WO (1)	WO1996012022A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5075222A (en) *	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US5872095A (en) *	1990-05-01	1999-02-16	Chiron Corporation	IL-1 receptor antagonists medicaments
US6380162B1 (en) *	1996-10-31	2002-04-30	Applied Research Systems Ars Holding N.V.	Ice inhibiting peptides
ES2312179T3 (es) *	1996-12-06	2009-02-16	Amgen Inc.	Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
IL126562A0 (en) *	1998-10-14	1999-08-17	Interpharm Lab Ltd	Expression and secretion of icil-1 receptor antagonist type ii
US20020077276A1 (en) *	1999-04-27	2002-06-20	Fredeking Terry M.	Compositions and methods for treating hemorrhagic virus infections and other disorders
US7166712B2 (en) *	2000-07-12	2007-01-23	Philadelphia, Health And Education Corporation	Mammalian MDM2 binding proteins and uses thereof
PL3718564T3 (pl) *	2003-12-23	2024-03-18	Genentech, Inc.	Nowe przeciwciała anty-IL 13 i ich zastosowania
ES2706848T3 (es)	2004-07-06	2019-04-01	Zymogenetics Inc	Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
RU2326947C2 (ru) *	2004-11-23	2008-06-20	Общество с ограниченной ответственностью "ЦИТОКИН"	Способ получения рекомбинантного антагониста рецептора интерлейкина-1 человека "арил"
BRPI0706788A2 (pt) *	2006-01-31	2011-04-05	Novartis Ag	anticorpos antagonistas il-17
CN101918018B (zh)	2007-11-14	2012-12-05	再生医药有限公司	使用白介素-1受体拮抗剂作为骨髓保护剂的方法
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
ES2600616T3 (es)	2011-03-14	2017-02-10	Phlogo Aps	Antagonistas del receptor de la interleucina-1
US9156897B2 (en)	2012-06-08	2015-10-13	Alkermes, Inc.	Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2015191783A2 (en)	2014-06-10	2015-12-17	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
EA202191354A1 (ru) *	2018-11-15	2021-08-11	Янссен Байотек, Инк.	Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0148009B1 (ko) *	1988-05-27	1998-08-01	그래고리 비. 아보트	인터루킨-1 억제제
EP0502956B1 (de) *	1989-11-29	1997-04-23	Amgen Boulder Inc.	Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
AU649245B2 (en) *	1990-04-02	1994-05-19	Amgen, Inc.	Methods for treating interleukin-1 mediated diseases
WO1991017184A1 (en) *	1990-04-27	1991-11-14	The Upjohn Company	Modified interleukin-1 inhibitors
AU655766B2 (en) *	1990-05-01	1995-01-12	Chiron Corporation	Interleukin-1 antagonist and uses thereof

1994
- 1994-10-13 IT ITMI942097A patent/IT1270662B/it active IP Right Grant
1995
- 1995-06-07 US US08/476,860 patent/US5739282A/en not_active Expired - Fee Related
- 1995-10-12 MX MX9702616A patent/MX9702616A/es not_active IP Right Cessation
- 1995-10-12 AT AT95936482T patent/ATE303439T1/de not_active IP Right Cessation
- 1995-10-12 CA CA002202470A patent/CA2202470C/en not_active Expired - Fee Related
- 1995-10-12 EP EP95936482A patent/EP0786002B1/de not_active Expired - Lifetime
- 1995-10-12 RU RU97107461/13A patent/RU2193064C2/ru not_active IP Right Cessation
- 1995-10-12 JP JP8512932A patent/JPH10509306A/ja active Pending
- 1995-10-12 ES ES95936482T patent/ES2243942T3/es not_active Expired - Lifetime
- 1995-10-12 CN CNB200510053993XA patent/CN100363053C/zh not_active Expired - Fee Related
- 1995-10-12 EE EE9700090A patent/EE03697B1/xx not_active IP Right Cessation
- 1995-10-12 BR BR9509317A patent/BR9509317A/pt not_active Application Discontinuation
- 1995-10-12 PT PT95936482T patent/PT786002E/pt unknown
- 1995-10-12 WO PCT/EP1995/004023 patent/WO1996012022A1/en not_active Ceased
- 1995-10-12 KR KR1019970701931A patent/KR100237936B1/ko not_active Expired - Fee Related
- 1995-10-12 CN CNB951956647A patent/CN1224707C/zh not_active Expired - Fee Related
- 1995-10-12 DE DE69534419T patent/DE69534419T2/de not_active Expired - Fee Related
- 1995-12-10 UA UA97052129A patent/UA65522C2/uk unknown
1997
- 1997-04-09 NO NO19971624A patent/NO320494B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69534419D1 (de)	2005-10-06
CA2202470C (en)	2008-09-16
DE69534419T2 (de)	2006-06-14
EP0786002B1 (de)	2005-08-31
IT1270662B (it)	1997-05-07
NO320494B1 (no)	2005-12-12
CA2202470A1 (en)	1996-04-25
NO971624L (no)	1997-05-30
BR9509317A (pt)	1997-10-14
CN100363053C (zh)	2008-01-23
ATE303439T1 (de)	2005-09-15
WO1996012022A1 (en)	1996-04-25
KR970706391A (ko)	1997-11-03
NO971624D0 (no)	1997-04-09
RU2193064C2 (ru)	2002-11-20
EP0786002A1 (de)	1997-07-30
CN1679919A (zh)	2005-10-12
ES2243942T3 (es)	2005-12-01
KR100237936B1 (ko)	2000-01-15
JPH10509306A (ja)	1998-09-14
AU701471B2 (en)	1999-01-28
CN1224707C (zh)	2005-10-26
EE9700090A (et)	1997-10-15
MX9702616A (es)	1998-04-30
EE03697B1 (et)	2002-04-15
ITMI942097A0 (it)	1994-10-13
AU3841795A (en)	1996-05-06
ITMI942097A1 (it)	1996-04-13
CN1161058A (zh)	1997-10-01
US5739282A (en)	1998-04-14
HK1002659A1 (en)	1998-09-11
PT786002E (pt)	2005-11-30
HK1081124A1 (zh)	2006-05-12

Publication	Publication Date	Title
UA65522C2 (en)	2004-04-15	Inner cellular isoform of interleukin-1 receptor antagonist
Liu et al.	2000	Human junction adhesion molecule regulates tight junction resealing in epithelia
EP0408859B1 (de)	1995-08-09	Monoklonale Antikörper gegen aktivierte endotheliale Zellen
Bouchard et al.	2007	G protein‐coupled receptor 84, a microglia‐associated protein expressed in neuroinflammatory conditions
FI105276B (fi)	2000-07-14	Diagnostinen järjestelmä, jossa käytetään peptidejä ja vasta-aineita, jotka inhiboivat verihiutaleadheesiota
Lin et al.	2005	Microtubule actin crosslinking factor 1b: a novel plakin that localizes to the Golgi complex
Umemoto et al.	2006	Nepmucin, a novel HEV sialomucin, mediates L-selectin–dependent lymphocyte rolling and promotes lymphocyte adhesion under flow
JPH05507406A (ja)	1993-10-28	人体適応化キメラ抗ｉｃａｍ―１抗体、製造方法および用途
TR201816574T4 (tr)	2018-11-21	Anti-ılt7 antikoru.
Lee et al.	1986	Murine B cell hybridomas bearing ligand-inducible Fc receptors for IgE.
Cai et al.	2019	Genome‐wide CRISPR‐Cas9 viability screen reveals genes involved in TNF‐α‐induced apoptosis of human umbilical vein endothelial cells
WO2022117049A1 (zh)	2022-06-09	Nkg2d car-免疫细胞在抗衰老及老年相关疾病治疗中的应用
Davidson et al.	2004	Distribution and immunoregulatory properties of antisecretory factor
Xiao et al.	2001	Down‐regulation of L‐type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits
WO2023143425A1 (zh)	2023-08-03	改善认知障碍的方法
Chang et al.	2019	Characterization of Two EF‐hand Domain‐containing Proteins from Toxoplasma gondii
Navenot et al.	1996	Expression of Glycosyl-Phosphatidylinositol-Linked Glycoproteins in Blood Cells from Paroxysmal Nocturnal Haemoglobinuria Patients a Flow Cytometry Study using CD55, CD58 and CD59 Monoclonal Antibodies
EP0505749A2 (de)	1992-09-30	Gegen aktivierte Endothelialzellen gerichtete monoklonale Antikörper und deren therapeutische und diagnostische Verwendung
US20260102486A1 (en)	2026-04-16	Use of nkg2d-based cell adapter molecule in removal of aging cells
US9296827B2 (en)	2016-03-29	Methods and compositions for modulating T cell and/or B cell activation
RU2186783C2 (ru)	2002-08-10	Кроличья антисыворотка, ингибирующая транспорт катионных аминокислот, и содержащая ее фармацевтическая композиция
CN105968199B (zh)	2019-07-02	抗电压门控钾通道1.3胞外环肽段的单克隆抗体及应用
CN100497625C (zh)	2009-06-10	一种癌症基因及其医药用途
Springer et al.	1985	Functional and structural interrelationships among the Mac-1, LFA-1 family of leukocyte adhesion glycoproteins, and their deficiency in a novel heritable disease
JP3715313B2 (ja)	2005-11-09	ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用